Global Radiotherapeutics Company Full-Life Technologies Announces Usd $47.3 Million Series B Financing, Prosperity7 Ventures Jointly Leads The Round

Jan 04, 2024•over 1 year ago

Amount Raised

$47.3 Million

Round Type

series b

ShanghaiPharmaceutical Manufacturing

Investors

Junson CapitalHong ShanChengwei CapitalGuanghua Wutong FundSummer CapitalSky9 CapitalProsperity7 Ventures

Description

Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. The financing will advance development of the Company's radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. With completion of such financing, Full-Life has secured more than $110 million funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies.

Company Information

Company

Full-Life Technologies

Location

Shanghai, Shanghai, China

About

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends